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The study objective was to test the hypothesis that simvastatin and fenofibrate should cause an increase in 
butyrylcholinesterase (BuChE) activity not only in the plasma and liver but also in the brain of normolipidemic and 
hyperlipidemic rats. Catalytic enzyme activity was measured using acetylthiocholine (ATCh) and butyrylthiocholine 
(BTCh) as substrates. Normolipidemic and hyperlipidemic rats were divided in four groups receiving 50 mg/kg of 
simvastatin a day or 30 mg/kg of fenofibrate a day for three weeks and three control groups receiving saline. Simvastatin 
and fenofibrate caused an increase in brain BuChE activity in both normo- and hyperlipidemic rats regardless of the 
substrate. The increase with BTCh as substrate was significant and practically the same in normolipidemic and 
hyperlipidemic rats after simvastatin treatment (14–17% vs controls). Simvastatin and fenofibrate also increased liver 
and plasma BuChE activity in both normolipidemic and hyperlipidemic rats regardless of the substrate. In most cases the 
increase was significant. Considering the important role of BuChE in cholinergic transmission as well as its pharmacological 
function, it is necessary to continue investigations of the effects of lipid-lowering drugs on BuChE activity.
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Butyrylcholinesterase (BuChE), also known as 
pseudocholinesterase (PChE) and plasma cholinesterase 
(EC 3.1.1.8), is synthesised in the liver and secreted into 
the blood circulation (1, 2). BuChE is found in the blood, 
pancreas, liver, central nervous system, and other tissues, 
but its function and endogenous substrate have not yet been 
established (3). Some authors propose that increased plasma 
BuChE activity in humans is associated with an abnormal 
lipid metabolism (1, 2, 4, 5). This enzyme is biochemically 
related to acetylcholinesterase (AChE, EC 3.1.1.7), and 
although it is less substrate-specific for acetylcholine (ACh) 
than AChE, BuChE is the major ACh-hydrolysing enzyme 
in the circulation (6). In the brain, BuChE is involved in 
ACh hydrolysis together with AChE and serves as a co-
regulator of cholinergic transmission. BuChE also 
hydrolyses a variety of other choline esters including 
butyrylcholine (BCh), propionylcholine, succinylcholine, 
and the aminoester local anaesthetics. According to new 
research (7), this enzyme is also involved in the degradation 
of ghrelin, a hormone responsible for the sensation of 
hunger.
Different drugs may either decrease or increase the 
activity of BuChE and AChE. Inhibition of plasma BuChE 
in rats and humans may be caused by organophosphorus 
herbicides such as glyphosate (8), reversible cholinesterase 
inhibitors (9), glucocorticoids (10, 11), or some beta 
blockers (12). In humans, low plasma BuChE activity may 
reduce succinylcholine hydrolysis and prolong respiratory 
depression (13). In contrast, brain inhibition of BuChE and 
AChE activity may be beneficial for the therapy of older 
population, as the inhibitors of both enzymes enhance the 
activity of cholinergic neurons in the brain, which is of 
particular benefit in patients with Alzheimer’s disease, who 
have decreased forebrain cholinergic neuron count and a 
progressive decrease in ACh (14, 15).
Like many other, lipid-lowering drugs affect enzyme 
activity. Several in vitro and in vivo non-clinical 
investigations have evidenced that statins either decrease 
or have no effect on AChE and BuChE activity (16, 17). 
Our recent study, however, has shown that simvastatin 
significantly increases plasma and liver BuChE activity in 
normolipidemic rats (18). Fibrates have also been shown 
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to increase BuChE activity in non-clinical studies (19, 20). 
Clinical evidence, in turn, is still not strong enough to reach 
definitive conclusions about the effects of lipid-lowering 
agents on plasma BuChE activity (4, 21).
Because of the pharmacological function of BuChE in 
plasma, its role in the brain cholinergic system, and the 
widespread therapeutic use of lipid-lowering drugs, we 
extended our investigation to include the effect of lipid-
lowering agents on brain BuChE activity and test the 
hypothesis that they should increase brain BuChE activity 
like they do in the plasma and liver. Simvastatin and 
fenofibrate as representatives of statins and fibric acid 
derivatives were chosen for this investigation because both 
agents cross the blood-brain barrier. We also wanted to see 
if the increase in brain, plasma, and liver enzyme activity 
would be greater in hyperlipidemic rats.
MATERIALS AND METHODS
Test substances
Simvastatin (CAS-79902-63-9) (Lipex®, Merck Sharp 
& Dohme, Haarlem, the Netherlands) and fenofibrate (CAS-
49562-28-9) (Tricor®, Recipharm Fontaine, Fontaine-lès-
Dijon, France) tablets were suspended in 5 mL/kg saline 
and administered daily between 9.00 and 10.00 a.m. by oral 
gavage.
Animals
Normolipidemic Wistar rats weighing 250–300 g were 
obtained from the Department of Pharmacology, University 
of Zagreb School of Medicine, Croatia, whereas the 
hyperlipidemic Zucker rats (HsdOla: Zucker-Lepr fa-fa) 
weighing 270–300 g were obtained from Harlan Laboratories 
srl., Udine, Italy. The animals were kept under controlled 
laboratory conditions and receiving standard pelleted diet 
ad libitum. Handling and treatment followed the FELASA 
guidelines and recommendations for the use of laboratory 
animals (22). The experiments had been approved by the 
local committee of the Zagreb University School of 
Medicine.
Study design
Normolipidemic rats were randomly divided in two 
experimental (N=10 each) and two control groups (N=8 
each). One experimental group received 50 mg/kg of 
simvastatin a day and the other 30 mg/kg of fenofibrate a 
day. Control groups received 0.9% NaCl solution, as it was 
solvent for drugs in the experimental groups. The route of 
administration was the same as in the experimental groups 
(oral gavage). Hyperlipidemic Zucker rats were also 
randomly divided in two experimental and one control 
group. One experimental group (N=7) received simvastatin 
and the other (N=8) fenofibrate in the same doses and way 
as the normolipidemic rats. The control group (N=6) 
received saline as above.
The experimental treatment lasted 21 days. On day 22, 
after a 12-hour overnight fast, all animals were sacrificed 
under diethyl ether anaesthesia (23). Blood samples for the 
measurement of BuChE activity were obtained by cardiac 
puncture and frozen at -20 °C immediately after sampling 
until further processing. Liver and brain tissue for the 
determination of BuChE activity was frozen at -70 °C. 
Before collecting, blood was washed from the liver with 
saline in situ through the superior vena cava. The brain was 
also rinsed with saline.
Measurement of BuChE activity in the brain, plasma, and 
liver
The catalytic activity of BuChE in the brain, plasma, 
and liver was measured spectrophotometrically as described 
by Ellman et al. (24) using butyrylthiocholine (BTCh) 
(0.9 mmol/L) and acetylthiocholine (ATCh) (0.6 mmol/L) 
as substrates (Sigma ChemCo, St. Louis, MO, USA). Whole 
brains weighing 1.8 to 2.2 g and small portions of liver 
weighing 0.7 to 0.98 g were homogenised in four volumes 
of saline and centrifuged at 3500 x g for 15 min. The 
reaction mixture for the hydrolysis in the brain, plasma, and 
liver contained 1 mL of a mixture of 3 mL 0.1 mol phosphate 
buffer and 100 µL of 0.38 mmol/L 5.5-dithio-bis 
(2-nitrobenzoic acid) (DTNB), 100 µL of BTCh or 100 µL 
of ATCh, and 50 µL of plasma or 50 µL of brain or liver 
homogenate. The reaction for the measurement of BuChE 
activity in the liver tissue was repeated after the addition 
of 50 µL of ethopropazine hydrochloride, which is a specific 
BuChE inhibitor. The increase in absorbance at 412 nm and 
at 25 °C was monitored for 3 min. A blank sample 
containing the incubation mixture without the brain, plasma, 
and liver homogenate was run simultaneously to correct for 
the spontaneous substrate breakdown. Enzyme activities 
were expressed as μmol/L of substrate hydrolysed per min 
per mL of plasma or g of tissue.
Data analysis
Data were analysed using Dunnett’s multiple comparison 
test, which compares treatment groups with controls (25). 
All tests were two-tailed, and the P values of <0.05 were 
considered statistically significant. All calculations and data 
plotting were done using GraphPad Prism for Windows 
version 7 (GraphPad Software, San Diego, CA, USA).
RESULTS AND DISCUSSION
Brain, plasma, and liver BuChE activity in 
normolipidemic rats
Table 1 shows brain, plasma, and liver BuChE activity 
in normolipidemic rats. Brain BuChE activity measured 
with ATCh was not significantly affected by simvastatin 
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Our results confirm our hypothesis that simvastatin and 
fenofibrate would increase brain BuChE activity in both 
normolipidemic and hyperlipidemic rats regardless of the 
type of substrate used to measure enzyme activity. The 
exception is brain BuChE activity in normolipidemic rats 
when ATCh was used as substrate. The reason is higher 
affinity of BuChE for BTCh than for ATCh, i.e. the enzyme 
is less substrate-specific for ACh. Since BuChE is 
biochemically related to AChE, we believe that this 
difference in substrate sensitivity is not an obstacle to 
interpret our results in light of reports of AChE activity. 
Cibicková et al. (17) were the first to show the inhibitory 
effect of simvastatin and atorvastatin on brain AChE activity 
in the frontal cortex of rats. Their second study (26), in 
contrast, found no change in brain AChE activity. Dalla et 
al. (27) also reported that simvastatin and pitavastatin had 
no effect on brain AChE activity in rats on normal diet. 
These studies and our investigations suggest that statins 
have different effect on BuChE and AChE activity.
We cannot, however, interpret the fenofibrate-induced 
increase in brain BuChE activity in light of other studies, 
as none have been published so far. Fenofibrate showed 
similar effects to simvastatin on brain BuChE activity, i.e. 
increase in its activity, as it causes a faster hydrolysis of 
ACh and consequently affects brain cholinergic transmission. 
In patients on long-term statin or fibrate therapy, the increase 
in brain BuChE activity could therefore cause side effects.
Simvastatin and fenofibrate in our study also caused 
higher liver and plasma BuChE activity in both rat strains 
regardless of the used substrate (Tables 1 and 2), but the 
and fenofibrate. In plasma its activity increased 22% 
(p=0.029) with simvastatin and 48% (p=0.003) with 
fenofibrate vs control (Table 1). In the liver BuChE catalytic 
activity soared 83% (p=0.013) with fenofibrate vs control, 
while the increase of 19% with simvastatin was not 
statistically significant (Table 1).
When BTCh was used as substrate, simvastatin 
increased brain BuChE activity 17% vs control (p=0.043), 
and fenofibrate caused only mild changes. In the plasma, 
BuChE activity increased 57% with simvastatin (p<0.001) 
and 63% with fenofibrate (p=0.003). Liver BuChE activity 
increased 85% (p=0.009) with fenofibrate, while simvastatin 
caused only a mild increase.
Brain, plasma, and liver BuChE activity in 
hyperlipidemic rats
Table 2 shows brain, plasma, and liver BuChE activity 
in hyperlipidemic rats. Measured with ATCh as substrate 
brain BuChE activity increased 18% vs control (p=0.008) 
with simvastatin and 7% with fenofibrate (p>0.05). Plasma 
BuChE activity increased 56% (p<0.001) and 84% 
(p<0.001), whereas liver BuChE activity increased 40% 
(p<0.001) and 59% (p<0.001) vs control, respectively.
With BTCh used as substrate brain BuChE activity 
increased 14% (p<0.001) with both simvastatin and 
fenofibrate. Plasma BuChE activity increased 94% with 
simvastatin and as high as 144% with fenofibrate (p<0.001), 
whereas liver BuChE activity increased 103% (p=0.003) 
with simvastatin and only 26% with fenofibrate (p>0.05).
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Table 1 Effects of simvastatin (50 mg/kg daily for three weeks) and fenofibrate (30 mg/kg daily for three weeks) on brain, plasma, 
















































































































Bolded P values are significant at the <0.05 level; ATCh – acetylthiocholine, BTCh – butyrylthiocholine, BuChE – butyrylcholinesterase; 
a values are mean ± SD; b P value of independent two-sample t-test; c 95% confidence interval for difference between means
33Vukšić A, et al. Effects of simvastatin and fenofibrate on BChE activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats Arh Hig Rada Toksikol 2019;70:30-35
effect was mostly stronger in hyperlipidemic rats. In some 
cases BuChE activity was higher when BTCh was used as 
substrate (Table 1), especially in hyperlipidemic rats (Table 
2). A possible reason why simvastatin and fenofibrate should 
cause higher enzyme activity in the plasma and liver of 
hyperlipidemic rats is their pathophysiological condition.
Higher BuChE activity in this study confirms our 
previous findings for simvastatin and gemfibrozil, the other 
member of fibric acid derivatives, as well as the results 
reported by other authors who showed that clofibrate, 
gemfibrozil, and fenofibrate significantly increased serum 
and liver BuChE activity in rats and mice (28–30). In 
contrast, Cibicková et al. (26) did not prove any influence 
of simvastatin and atorvastatin on either AChE or BuChE 
in the blood.
The significant increase in liver and plasma BuChE 
activity caused by simvastatin and fenofibrate is likely a 
consequence of the higher expression of peroxisome 
proliferator-activated receptor alpha (PPARα), which is a 
well known transcriptional factor (31–33). In rodents 
PPARα is primarily expressed in the liver and adipose tissue 
and, to a lesser extent, in the kidney, heart, and skeletal 
muscles. It plays an important role in lipid homeostasis, as 
it influences fatty acid metabolism and its activation lowers 
lipid levels in animals and humans (34–36).
According to Ferreira et al. (37), fenofibrate treatment 
increased PPAR alpha and gamma receptors in rat adipose 
tissue and in consequence of their activation also increased 
the expression of some oxidative enzymes. It had the same 
effect on oxidative enzymes in rat liver (37–39). This 
suggests that the activation of PPARα receptor also stands 
behind fenofibrate increasing BuChE expression in the liver.
PPARα receptors have recently been reported in some 
brain regions, where they probably have an important role 
in brain lipid metabolism (40, 41). Berger et al. (42) have 
also suggested that specific fatty acids that play a crucial 
role in neural cells and are essential components of myelin 
are synthesised in peroxisomes. Further research should 
answer whether higher brain BuChE activity in our study 
is partly owed the agonistic effects of simvastatin and 
fenofibrate on brain PPARα receptors and on these special 
fatty acids.
It is known for a fact that rodents are more susceptible 
to peroxisome proliferators than dogs, rhesus monkeys, or 
humans. Probably this difference in PPARα receptor 
sensitivity to statins and fibrates is the reason why statins 
either do not affect or lower plasma enzyme activity in 
humans (4, 21, 43).
Clinical investigations referred to above lasted no longer 
than six months, which begs the question whether long-term 
lipid-lowering therapy could change the sensitivity of 
PPARα and cause an increase rather than a decrease in 
BuChE activity in human patients.
In summary, our results clearly show that simvastatin 
and fenofibrate cause a similar increase in brain BuChE 
activity in normolipidemic and hyperlipidemic rats. Such 
increases in brain BuChE activity could lead to side effects 
in patients on long-term therapy with statins and fibrates. 
We have also verified our earlier findings that simvastatin 
and fibric acid derivatives increase liver and plasma BuChE 
activity. However, it is hard to extrapolate our findings in 
Table 2 Effects of simvastatin (50 mg/kg daily for three weeks) and fenofibrate (30 mg/kg daily for three weeks) on brain, plasma, 

































































































Bolded P values are significant at the <0.05 level; ATCh – acetylthiocholine, BTCh – butyrylthiocholine, BuChE – butyrylcholinesterase; 
a values are mean ± SD; b P value of independent two-sample t-test; c 95% confidence interval for difference between means
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humans at this point, because rats are more susceptible to 
peroxisome proliferators than humans. Future pre-clinical 
research should therefore focus on the molecular 
mechanisms of these changes.  Because of the 
pharmacological role of BuChE in plasma and brain 
cholinergic system, long-term clinical studies are also 
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Učinci simvastatina i fenofibrata na aktivnost butirilkolinesteraze u mozgu, plazmi i jetri normolipidemičnih i 
hiperlipidemičnih štakora
Cilj ispitivanja bio je u normolipidemičnih i hiperlipidemičnih štakora potvrditi pretpostavku da simvastatin (SIMV) i 
fenofibrat (FENO) ne uzrokuju samo povećanje aktivnosti butirilkolinesteraze (BuChE) u plazmi i jetri nego i povećavaju 
aktivnosti BuChE u mozgu. Katalitička aktivnost enzima mjerena je upotrebom acetiltiokolina (ATCh) i butiriltiokolina 
(BTCh) kao supstrata. Normolipidemični i hiperlipidemični štakori raspoređeni su u eksperimentalne skupine, koje su 
tri tjedna primale SIMV 50 mg/kg na dan ili FENO 30 mg/kg na dan, dok su kontrolne skupine primale fiziološku otopinu. 
I SIMV i FENO uglavnom su izazvali povećanje aktivnosti BuChE u mozgu obaju sojeva štakora bez obzira na korišteni 
supstrat. Aktivnosti BuChE mjerene BTCh kao supstratom bile su značajno veće u odnosu na kontrolne vrijednosti u 
mozgu normolipidemičih štakora nakon primjene SIMV te u mozgu hiperlipidemičnih štakora nakon primjene obaju 
agensa (14‒17%, p<0,001). Povećanje aktivnosti BuChE u plazmi i jetri nakon primjene SIMV i FENO izmjeren je u 
oba soja štakora bez obzira na to je li korišten ACTh ili BTCh. U većini slučajeva povećanje aktivnosti BuChE u plazmi 
i jetri bilo je značajno. S obzirom na važnu ulogu BuChE u kolinergičnom prijenosu te na njezinu farmakološku funkciju, 
potrebno je nastaviti istraživanja utjecaja antilipidnih lijekova na aktivnost BuChE.
KLJUČNE RIJEČI: acetiltiokolin; antilipidni lijekovi; butiriltiokolin; Wistar štakori; Zucker štakori
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